2019与2016 ESC/EAS他汀一级预防指南比较
中位随访9.2年,3337例发生ASCVD。2019指南使符合I/A类推荐的他汀资格比例从15.4%升至32.3%,预计可预防的ASCVD事件比例从11%升至25%,NNT相似(19 vs 20)。
要点
- 2019指南使符合I/A类推荐的他汀资格比例从15.4%升至32.3%,主要因年龄范围扩大和LDL-C阈值降低。
- 若完全实施,2019指南预计可预防25%的ASCVD事件,而2016指南为11%。
- 两指南的NNT相似(19 vs 20),主要因2019指南年龄范围扩大。
核心结论
- 2019较2016 ESC/EAS指南因LDL-C阈值降低和年龄范围扩大,使他汀一级预防资格人数翻倍,显著提高ASCVD预防潜力,且NNT相似。
主要发现
- 随访期间3337例发生ASCVD(心肌梗死、卒中、心血管死亡)。
- 2019和2016指南I/A类推荐的他汀资格比例分别为32.3%(95%CI 31.8-32.7)和15.4%(95%CI 15.1-15.7)。
- 资格增加的原因:单纯LDL-C阈值降低占33.2%,单纯年龄范围扩大占49.4%,两者联合占14.7%,SCORE风险算法更新占2.8%。
- 若完全实施高强度他汀10年,2019和2016指南预计可预防的ASCVD事件比例分别为25%和11%。
- 预防一例ASCVD事件的NNT分别为19(2019)和20(2016),主要因2019指南年龄范围扩大。
临床怎么用
- 临床中可参考2019 ESC/EAS指南,对40-75岁人群根据更低的LDL-C阈值和更宽的年龄范围评估他汀一级预防资格。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The 2019 vs. 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) dyslipidaemia guidelines contains new recommendations for primary prevention with statins; however, the potential impact of these changes is unclear. We compared the 2019 and 2016 guidelines regarding statin eligibility and potential impact on prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population. METHODS AND RESULTS: We examined 45 750 individuals aged 40-75 from the Copenhagen General Population Study, all free of ASCVD and statin use at baseline. During the 9.2-year follow-up, 3337 experienced ASCVD (myocardial infarction, stroke, and cardiovascular death). For Class I/A recommendations, 32.3% (95% confidence interval: 31.8-32.7) and 15.4% (15.1-15.7) of individuals were statin eligible according to the 2019 and 2016 guidelines. The increased statin eligibility by the 2019 guidelines was explained by lower low-density lipoprotein cholesterol (LDL-C) thresholds alone (explaining 33.2%), older age range alone (49.4%), older age range in combination with lower LDL-C thresholds (14.7%), and updated SCORE risk algorithm (2.8%). If fully implemented, the estimated percentage of ASCVD events that can be prevented by using high-intensity statins for 10 years were 25% and 11% with the 2019 and 2016 guidelines. Mainly because of older age range in the 2019 guidelines, the corresponding estimated numbers needed to treat (NNT) to prevent one ASCVD event were 19 and 20. CONCLUSION: Due to lower LDL-C threshold and older age range, the 2019 vs. 2016 ESC/EAS guidelines doubles the number of individuals eligible for primary prevention with statins. This considerably improves the potential for ASCVD prevention in the general population, with similar NNT to prevent one event.
引用
- Mortensen MB, Nordestgaard BG. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2020. PMID: 32227172. doi:10.1093/eurheartj/ehaa150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。